MSI 843

Drug Profile

MSI 843

Latest Information Update: 14 Aug 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genaera Corporation
  • Class Antibacterials; Peptide antibiotics; Peptides
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 03 Aug 1998 No-Development-Reported for Bacterial infections in USA (IV)
  • 23 Apr 1996 An in vitro study has been added in the antibacterial and pharmacodynamic sections .
  • 27 Oct 1995 Fisons of UK is to collaborate with Magainin Pharmaceuticals on the development and marketing of MSI 843.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top